Indication
Unresectable or metastatic Kit (CD117) positive gastrointestinal stromal tumor
An unresectable or metastatic Kit (CD117) positive gastrointestinal stromal tumor is an advanced mesenchymal malignancy of the digestive tract arising from the interstitial cells of Cajal or their precursors. Read more about Unresectable or metastatic Kit (CD117) positive gastrointestinal stromal tumor
28 drugs 27 manufacturers
Drugs that treat it
Common Unresectable or metastatic Kit (CD117) positive gastrointestinal stromal tumor therapies.
IMATINIB MESYLATE
IMATINIB (imatinib mesylate)
IMATINIB (imatinib mesylate)
IMATINIB (imatinib mesylate)
IMATINIB (imatinib mesylate)
IMATINIB MESYLATE
IMATINIB MESYLATE
IMATINIB MESYLATE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAn unresectable or metastatic Kit (CD117) positive gastrointestinal stromal tumor is an advanced mesenchymal malignancy of the digestive tract arising from the interstitial cells of Cajal or their precursors.
Pathophysiologically, the tumor is characterized by strong immunohistochemical expression of the CD117 cell-surface marker, which corresponds to the KIT receptor tyrosine kinase and is predominantly driven by activating mutations that stimulate unchecked cellular proliferation.
In this clinical state, the neoplasm has either grown to involve critical structures making complete surgical removal impossible (unresectable) or has disseminated to distant sites, most commonly the liver and peritoneum (metastatic).
Affected adult populations often present with abdominal masses, gastrointestinal bleeding, obstruction, or systemic symptoms associated with advanced abdominal malignancy.
- nih.gov
An unresectable or metastatic Kit (CD117) positive gastrointestinal stromal tumor is an advanced mesenchymal malignancy of the digestive tract arising from the interstitial cells of Cajal or their precursors Pathophysiologically, the tumor is characterized by strong immunohistochemical expression of the CD117 cell-surface marker, which corresponds to the KIT receptor tyrosine kinase and is predominantly driven by activating mutations that stimulate unchecked cellular proliferation In this clinic...
- nih.gov
An unresectable or metastatic Kit (CD117) positive gastrointestinal stromal tumor is an advanced mesenchymal malignancy of the digestive tract arising from the interstitial cells of Cajal or their precursors Pathophysiologically, the tumor is characterized by strong immunohistochemical expression of the CD117 cell-surface marker, which corresponds to the KIT receptor tyrosine kinase and is predominantly driven by activating mutations that stimulate unchecked cellular proliferation
- mdanderson.org
An unresectable or metastatic Kit (CD117) positive gastrointestinal stromal tumor is an advanced mesenchymal malignancy of the digestive tract arising from the interstitial cells of Cajal or their precursors In this clinical state, the neoplasm has either grown to involve critical structures making complete surgical removal impossible (unresectable) or has disseminated to distant sites, most commonly the liver and peritoneum (metastatic)
- nih.gov
Pathophysiologically, the tumor is characterized by strong immunohistochemical expression of the CD117 cell-surface marker, which corresponds to the KIT receptor tyrosine kinase and is predominantly driven by activating mutations that stimulate unchecked cellular proliferation Affected adult populations often present with abdominal masses, gastrointestinal bleeding, obstruction, or systemic symptoms associated with advanced abdominal malignancy
- dana-farber.org
In this clinical state, the neoplasm has either grown to involve critical structures making complete surgical removal impossible (unresectable) or has disseminated to distant sites, most commonly the liver and peritoneum (metastatic)
Personalize your experience
Follow Unresectable or metastatic Kit (CD117) positive gastrointestinal stromal tumor and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.